Multi-strain synbiotic supplementation (probiotic + prebiotic) as adjunctive therapy alongside antipsychotics. This is the strongest validated microbiome-targeted intervention for schizophrenia, with both psychiatric symptom improvement and metabolic benefit demonstrated at the meta-analysis level.
Evidence map4 cited passagesInspect provenance +
Strain selection determines success or failure. L. rhamnosus GG + B. animalis Bb12 (2-strain) showed no effect on PANSS scores (SMD = -0.0884, p = 0.551). Multi-strain formulations containing L. acidophilus, B. bifidum, L. reuteri, L. fermentum consistently showed benefit across multiple trials.
The validated formulation from Basafa-Roodi 2024 (, RCT, n=70): 12 strains (L. rhamnosus, L. casei, L. acidophilus, L. bulgaricus, L. plantarum, L. gasseri, L. helveticus, B. lactis, B. breve, B. longum, B. bifidus, S. thermophilus) + 21 mg FOS prebiotic, 8 weeks.
Source:
Source:
Critical: Strain Specificity#
Strain selection determines success or failure. L. rhamnosus GG + B. animalis Bb12 (2-strain) showed no effect on PANSS scores (SMD = -0.0884, p = 0.551).[1]A Systematic Review of the Effect of Probiotic Supplementation on Schizophrenia SymptomsNg QX, Soh AYS, Venkatanarayanan N et al. · 2019Open reference 1 ↓ Multi-strain formulations containing L. acidophilus, B. bifidum, L. reuteri, L. fermentum consistently showed benefit across multiple trials.
The validated formulation from Basafa-Roodi 2024 (,[2]Effects of Synbiotic Supplementation on the Components of Metabolic Syndrome in Patients with Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled TrialBasafa-Roodi P, Jazayeri S, Hadi F et al. · 2024Open reference 2 ↓ RCT, n=70): 12 strains (L. rhamnosus, L. casei, L. acidophilus, L. bulgaricus, L. plantarum, L. gasseri, L. helveticus, B. lactis, B. breve, B. longum, B. bifidus, S. thermophilus) + 21 mg FOS prebiotic, 8 weeks.
Evidence#
Meta-Analysis (Ye 2025)#
Design: Systematic review and meta-analysis of 10 RCTs (n=585). Psychiatric outcomes: Total PANSS significantly reduced (MD = -5.38, 95% CI -8.70 to -2.06, p = 0.001). Metabolic outcomes: Significant reductions in fasting blood sugar, triglycerides, total cholesterol, HOMA-IR, QUICKI (all p < 0.05).
No effect on: HDL, LDL, body weight, BMI, insulin levels. Source:.[3]Effects of Gut Microbiota Interventions on Patients with Schizophrenia: A Systematic Review and Meta-AnalysisYe N, Song X, Yu J et al. · 2025Open reference 3 ↓
RCT—Metabolic Syndrome Focus (Basafa-Roodi 2024)#
- Design: Double-blind RCT, n=70 (55 completed), 8 weeks
- Key outcomes: Significant decrease in waist circumference (-2.66 vs +3.03), HbA1c (-0.26 vs +0.20), LDL-c, triglycerides. BMI stable in synbiotic group but increased in placebo group (between-group p = 0.01)
- Context: Metabolic syndrome develops in ~1/3 of schizophrenia patients within the first few years of antipsychotic treatment
- Source:[2]Effects of Synbiotic Supplementation on the Components of Metabolic Syndrome in Patients with Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled TrialBasafa-Roodi P, Jazayeri S, Hadi F et al. · 2024Open reference 2 ↓
Mechanism#
Multi-strain synbiotics target the core ecological disruption in schizophrenia.
SCFA restoration: Reintroduce butyrate-producing species lost in schizophrenia (Faecalibacterium, Roseburia, Coprococcus, Blautia depleted across 4+ studies). Gut barrier repair: Butyrate strengthens tight junctions, reducing the bacterial translocation documented in schizophrenia (endotoxin antibodies SMD = 2.72). Anti-inflammatory cascade: Reduced systemic inflammation (CRP) → reduced neuroinflammation → reduced microglial M1 polarization.
Metabolic stabilization: Counteracts antipsychotic-induced metabolic syndrome—the primary driver of the 15-20 year life expectancy reduction.
Clinical Context#
This intervention is adjunctive—it does not replace antipsychotics. The clinical value is dual: modest psychiatric symptom improvement AND metabolic syndrome prevention/reversal. Given that metabolic comorbidities drive the majority of excess mortality in schizophrenia, the metabolic benefit may be more clinically significant than the PANSS reduction.
References 3
Numbered by first appearance in the article, then reconciled with its declared source list.
- 1
Ng QX, Soh AYS, Venkatanarayanan N et al. (2019). A Systematic Review of the Effect of Probiotic Supplementation on Schizophrenia Symptoms. Neuropsychobiology.
- 2
Basafa-Roodi P, Jazayeri S, Hadi F et al. (2024). Effects of Synbiotic Supplementation on the Components of Metabolic Syndrome in Patients with Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial. BMC Psychiatry.
- 3
Ye N, Song X, Yu J et al. (2025). Effects of Gut Microbiota Interventions on Patients with Schizophrenia: A Systematic Review and Meta-Analysis. Frontiers in Microbiology.
Article network
Mentioned here 1
Pages linking here 2
Connect the evidence
Publicly readable discussion by ORCID-authenticated researchers. Questions, interpretation, methods, corrections, and new evidence stay attached to this record.
No discussion yet. Start with a precise question or a source-backed observation.
Activity and accepted changes
Accepted researcher context, editorial status, public discussion, and upstream Git revisions are shown together. Pending, declined, and withdrawn proposals remain private.
- published revision
Deepen metal/concept entities + 8 new sources for T1D/schizophrenia
WikiBiome Deploy Bot · +70 −0
Inspect exact Git diff ↗